Toggle Health Problems and D

Itchy skin (pruritus) due to kidney disease was treated with topical vitamin D – April 2015

Effect of topical vitamin D on chronic kidney disease-associated pruritus: An open-label pilot study

Japanese Dermatological Association, Article first published online: 28 APR 2015
DOI: 10.1111/1346-8138.12895
Kyung Eun Jung1, Yu Ri Woo1, Joong Sun Lee1, Jong Ho Shin2, Jin Uk Jeong2, Dae Won Koo1 andKi Tae Bang2,*
1Department of Dermatology, School of Medicine, Eulji University Hospital, Daejeon, Korea
2Department of Internal Medicine (Nephrology), School of Medicine, Eulji University Hospital, Daejeon, Korea
*Correspondence: Ki Tae Bang, Ph.D., M.D., Department of Nephrology, Eulji University Hospital, School of Medicine, Eulji University, 95 Dunsanseo-ro, Daejeon 302-799, Korea. Email: starryroom at eulji.ac.kr

Chronic kidney disease-associated pruritus (CKD-aP) is a troublesome symptom in patients with end-stage renal disease (ESRD). Recently, vitamin D deficiency has been known to be one of the possible etiologic factors in CKD-aP. However, limited data is available on whether topical vitamin D treatment is effective for relieving CKD-aP. Therefore, the purpose of this study is to evaluate the effectiveness of topically vitamin D for CKD-aP.

Twenty-three patients with CKD-aP were enrolled in a single center, open-label study. Patients were instructed to apply a topical vitamin D (calcipotriol) agent (Daivonex solution; LEO Pharma) or vehicle solution twice daily for a month. We assessed the efficacy and safety of topical vitamin D on CKD-aP using clinical and dermoscopic photographs, and questionnaires including the validated modified pruritus assessment score (VMPAS) and visual analog scale (VAS) every 2 weeks. Dry dermoscopic findings showed significant improvement of scale (dryness) on the skin of topical vitamin D-treated patients compared with those of the vehicle group. Both VMPAS and VAS were significantly decreased after 2 and 4 weeks of the topical vitamin D treatment compared with the vehicle, respectively (P < 0.05). No significant side-effects were observed. Topical vitamin D may be one of the safe and effective therapeutic candidates for CKD-aP.

Publisher rents the PDF for $6
The following two items are previews provided by the publisher

Image Image

See also VitaminDWiki

Attached files

ID Name Comment Uploaded Size Downloads
5384 Puritus chart.jpg admin 28 Apr, 2015 12:47 15.68 Kb 1111
5383 puritus.jpg admin 28 Apr, 2015 12:47 119.07 Kb 1224